N2OFF stockholders approve MitoCareX Bio acquisition

N2OFF stockholders have approved the acquisition of MitoCareX Bio Ltd. from SciSparc Ltd., marking a strategic pivot for N2OFF from its cleantech focus to include cancer therapeutics. The transaction, expected to close in early October 2025, entails N2OFF paying $700,000 cash to SciSparc, exchanging shares for 40% of its fully diluted capital with sellers, and committing an initial $1 million to MitoCareX's operations. This deal occurs despite SciSparc's recent stock decline, leveraging its strong liquidity and projected sales growth, though it involves related parties with shared board members and chairmanship.

Analysis

N2OFF, Inc. (NITO) has secured stockholder approval for the acquisition of MitoCareX Bio from SciSparc Ltd. (SPRC), signaling a fundamental strategic pivot from cleantech and solar assets to the high-risk, high-reward field of cancer therapeutics. The transaction structure involves a $700,000 cash payment to SciSparc and a significant 40% equity issuance in N2OFF to the sellers, with N2OFF committing an initial $1 million to fund MitoCareX's operations post-closing. This deal occurs while SciSparc, the seller, navigates a challenging period marked by a 44% stock decline over six months, though it maintains a strong liquidity position with a current ratio of 5.36x and minimal debt. Despite a recent revenue decline, analyst projections for SciSparc's sales growth of 17.3% in the coming year may provide some underlying support for its strategic divestments. A critical governance concern is the related-party nature of the transaction, as Mr. Amitay Weiss serves as Chairman of both companies, warranting investor scrutiny of the deal's terms. For N2OFF, this is a transformative, albeit dilutive, move into biotech, while for SciSparc, it represents a monetization event that provides non-dilutive capital and retains exposure to MitoCareX's potential upside through its new equity stake in N2OFF.

Key Decisions for Investors

• Investors in N2OFF should re-evaluate their position based on the company's complete strategic pivot from cleantech to high-risk biotechnology, factoring in the significant shareholder dilution and a long transaction runway with closing not expected until October 2025.
• For SciSparc, the transaction provides a modest cash infusion and retained upside in a focused biotech entity, but investors should weigh this against the company's very low market cap, poor recent stock performance, and scattered strategic focus across multiple unrelated initiatives.
• The presence of related parties, with the Chairman and a director serving on both boards, constitutes a material governance risk that requires investors to closely scrutinize the fairness of the transaction's terms and valuation.
• Key forward-looking indicators to monitor will be N2OFF's ability to secure financing to meet its $1 million operational commitment to MitoCareX and whether SciSparc can realize its projected 17.3% sales growth, which would validate its broader turnaround strategy.